Identification of a naturally occurring 21 bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment

Vincenzo De Luca, John B. Vincent, Daniel J. Müller, Rudi Hwang, Takahiro Shinkai, Jan Volavka, P. Czobor, Brian B. Sheitman, Jean Pierre Lindenmayer, Leslie Citrome, Joseph P. McEvoy, Jeffrey A. Lieberman, James L. Kennedy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Neurocognitive deficits are recognized as a cardinal feature of schizophrenia. Atypical antipsychotics have high affinity for many neurotransmitter receptors. Among these receptors, antipsychotics are antagonists of adrenoceptors, and this pharmacological property has been postulated to be involved in the mechanism of action of antipsychotics. We tested the hypotheses that clinical response and cognitive improvement to antipsychotic treatment are associated with genetic variation in adrenergic α2C receptor (ADRA2C). Fifty-seven patients with chronic schizophrenia were prospectively assessed for clinical response to antipsychotic treatment. They were subsequently genotyped for a 21 bp insertion/deletion that we identified in the 3′ untranslated region (3′UTR) of ADRA2C. With regard to clinical response and cognitive improvement to antipsychotics, there was no significant association observed for this polymorphism. Our results suggest that the novel polymorphism may not play a major role in antipsychotic response.

Original languageEnglish
Pages (from-to)381-384
Number of pages4
JournalPharmacological Research
Volume51
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

Antipsychotic Agents
Genes
Adrenergic Receptors
Therapeutics
Schizophrenia
Neurotransmitter Receptor
3' Untranslated Regions
Pharmacology

Keywords

  • Adrenergic α receptor (ADRA2C)
  • Antipsychotic response
  • Cognition
  • Polymorphism
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Identification of a naturally occurring 21 bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. / De Luca, Vincenzo; Vincent, John B.; Müller, Daniel J.; Hwang, Rudi; Shinkai, Takahiro; Volavka, Jan; Czobor, P.; Sheitman, Brian B.; Lindenmayer, Jean Pierre; Citrome, Leslie; McEvoy, Joseph P.; Lieberman, Jeffrey A.; Kennedy, James L.

In: Pharmacological Research, Vol. 51, No. 4, 04.2005, p. 381-384.

Research output: Contribution to journalArticle

De Luca, V, Vincent, JB, Müller, DJ, Hwang, R, Shinkai, T, Volavka, J, Czobor, P, Sheitman, BB, Lindenmayer, JP, Citrome, L, McEvoy, JP, Lieberman, JA & Kennedy, JL 2005, 'Identification of a naturally occurring 21 bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment', Pharmacological Research, vol. 51, no. 4, pp. 381-384. https://doi.org/10.1016/j.phrs.2004.10.013
De Luca, Vincenzo ; Vincent, John B. ; Müller, Daniel J. ; Hwang, Rudi ; Shinkai, Takahiro ; Volavka, Jan ; Czobor, P. ; Sheitman, Brian B. ; Lindenmayer, Jean Pierre ; Citrome, Leslie ; McEvoy, Joseph P. ; Lieberman, Jeffrey A. ; Kennedy, James L. / Identification of a naturally occurring 21 bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. In: Pharmacological Research. 2005 ; Vol. 51, No. 4. pp. 381-384.
@article{3fb39608c03043c6a12f0f9a0dca35b5,
title = "Identification of a naturally occurring 21 bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment",
abstract = "Neurocognitive deficits are recognized as a cardinal feature of schizophrenia. Atypical antipsychotics have high affinity for many neurotransmitter receptors. Among these receptors, antipsychotics are antagonists of adrenoceptors, and this pharmacological property has been postulated to be involved in the mechanism of action of antipsychotics. We tested the hypotheses that clinical response and cognitive improvement to antipsychotic treatment are associated with genetic variation in adrenergic α2C receptor (ADRA2C). Fifty-seven patients with chronic schizophrenia were prospectively assessed for clinical response to antipsychotic treatment. They were subsequently genotyped for a 21 bp insertion/deletion that we identified in the 3′ untranslated region (3′UTR) of ADRA2C. With regard to clinical response and cognitive improvement to antipsychotics, there was no significant association observed for this polymorphism. Our results suggest that the novel polymorphism may not play a major role in antipsychotic response.",
keywords = "Adrenergic α receptor (ADRA2C), Antipsychotic response, Cognition, Polymorphism, Schizophrenia",
author = "{De Luca}, Vincenzo and Vincent, {John B.} and M{\"u}ller, {Daniel J.} and Rudi Hwang and Takahiro Shinkai and Jan Volavka and P. Czobor and Sheitman, {Brian B.} and Lindenmayer, {Jean Pierre} and Leslie Citrome and McEvoy, {Joseph P.} and Lieberman, {Jeffrey A.} and Kennedy, {James L.}",
year = "2005",
month = "4",
doi = "10.1016/j.phrs.2004.10.013",
language = "English",
volume = "51",
pages = "381--384",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Identification of a naturally occurring 21 bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment

AU - De Luca, Vincenzo

AU - Vincent, John B.

AU - Müller, Daniel J.

AU - Hwang, Rudi

AU - Shinkai, Takahiro

AU - Volavka, Jan

AU - Czobor, P.

AU - Sheitman, Brian B.

AU - Lindenmayer, Jean Pierre

AU - Citrome, Leslie

AU - McEvoy, Joseph P.

AU - Lieberman, Jeffrey A.

AU - Kennedy, James L.

PY - 2005/4

Y1 - 2005/4

N2 - Neurocognitive deficits are recognized as a cardinal feature of schizophrenia. Atypical antipsychotics have high affinity for many neurotransmitter receptors. Among these receptors, antipsychotics are antagonists of adrenoceptors, and this pharmacological property has been postulated to be involved in the mechanism of action of antipsychotics. We tested the hypotheses that clinical response and cognitive improvement to antipsychotic treatment are associated with genetic variation in adrenergic α2C receptor (ADRA2C). Fifty-seven patients with chronic schizophrenia were prospectively assessed for clinical response to antipsychotic treatment. They were subsequently genotyped for a 21 bp insertion/deletion that we identified in the 3′ untranslated region (3′UTR) of ADRA2C. With regard to clinical response and cognitive improvement to antipsychotics, there was no significant association observed for this polymorphism. Our results suggest that the novel polymorphism may not play a major role in antipsychotic response.

AB - Neurocognitive deficits are recognized as a cardinal feature of schizophrenia. Atypical antipsychotics have high affinity for many neurotransmitter receptors. Among these receptors, antipsychotics are antagonists of adrenoceptors, and this pharmacological property has been postulated to be involved in the mechanism of action of antipsychotics. We tested the hypotheses that clinical response and cognitive improvement to antipsychotic treatment are associated with genetic variation in adrenergic α2C receptor (ADRA2C). Fifty-seven patients with chronic schizophrenia were prospectively assessed for clinical response to antipsychotic treatment. They were subsequently genotyped for a 21 bp insertion/deletion that we identified in the 3′ untranslated region (3′UTR) of ADRA2C. With regard to clinical response and cognitive improvement to antipsychotics, there was no significant association observed for this polymorphism. Our results suggest that the novel polymorphism may not play a major role in antipsychotic response.

KW - Adrenergic α receptor (ADRA2C)

KW - Antipsychotic response

KW - Cognition

KW - Polymorphism

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=20144383702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144383702&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2004.10.013

DO - 10.1016/j.phrs.2004.10.013

M3 - Article

C2 - 15683753

AN - SCOPUS:20144383702

VL - 51

SP - 381

EP - 384

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -